AOD-9604

AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 176-191 with a tyrosine substitution at the N-terminus. The name stands for Anti-Obesity Drug 9604, reflecting its original development purpose at Monash University in Australia during the 1990s by Professor Frank Ng. AOD-9604 was designed to isolate the lipolytic (fat-burning) properties of human growth hormone while avoiding the broader metabolic effects associated with full-length hGH, particularly its impact on insulin-like growth factor-1 (IGF-1) levels and glucose metabolism. The peptide retains the fat-reducing activity of human growth hormone without the muscle- building, growth-promoting, or diabetogenic effects. Between 2001 and 2007, AOD-9604 underwent extensive clinical development by Metabolic Pharmaceuticals Ltd. The peptide completed six randomized, double-blind, placebo-controlled human trials involving over 900 participants. Despite demonstrating an excellent safety profile and modest weight reduction in early Phase IIa trials, the largest Phase IIb trial (24 weeks, 502 participants) failed to demonstrate statistically significant weight loss compared to placebo. Development was terminated in 2007, and the peptide never received regulatory approval from any major health authority. Today, AOD-9604 remains available as a research peptide. While it failed as an obesity drug, research has revealed potential applications in cartilage repair and osteoarthritis treatment. The peptide continues to be studied for its unique mechanism of action targeting adipose tissue metabolism without systemic hormonal disruption.

How It Works

AOD-9604 works through multiple mechanisms centered on adipose tissue metabolism, primarily via beta-3 adrenergic receptor activation.

Beta-3 Adrenergic Receptor Activation

The primary mechanism of action involves selective activation of beta-3 adrenergic receptors (β3-AR) located on adipocytes (fat cells). Research in obese mice demonstrated that chronic AOD-9604 treatment upregulates beta-3 adrenergic receptor RNA expression, restoring levels comparable to those found in lean mice. This receptor upregulation enhances the tissue’s capacity for lipolysis and fat oxidation. Studies using beta-3 adrenergic receptor knockout mice confirmed the specificity of this mechanism. In these genetically modified animals, AOD-9604 produced no changes in body weight or lipolysis, demonstrating that the β3-AR pathway is essential for the peptide’s metabolic effects. When AOD-9604 activates beta-3 receptors, it initiates a signaling cascade: increased intracellular cyclic AMP (cAMP) levels through adenylyl cyclase stimulation, activation of information found in this book should be regarded as advice and opinions based on my experience and research. protein kinase A (PKA), phosphorylation and activation of hormone-sensitive lipase, and breakdown of stored triglycerides into free fatty acids that can be released into the bloodstream and oxidized for energy.

Lipolysis Stimulation

AOD-9604 directly stimulates hormone-sensitive lipase and promotes the breakdown of stored triglycerides into free fatty acids and glycerol. Research shows the peptide preferentially acts on obese fat cells rather than lean adipocytes, suggesting selectivity for pathological fat deposits. In animal studies, AOD-9604 treatment increased lipolytic activity in adipose tissue and enhanced fat oxidation rates. The peptide appears to work specifically during fasted states when insulin levels are low, as elevated insulin from food intake activates opposing lipogenic (fat- storing) pathways that can blunt the peptide’s fat-mobilizing effects.

Lipogenesis Inhibition

In addition to promoting fat breakdown, AOD-9604 inhibits lipogenesis (the formation of new fat). The peptide downregulates acetyl-CoA carboxylase activity in hepatocytes and adipocytes, the rate-limiting enzyme in fatty acid synthesis. This dual action of simultaneously promoting fat breakdown while reducing fat storage creates a net effect of adipose tissue reduction.

Metabolic Selectivity

Unlike full-length human growth hormone, AOD-9604 does not elevate IGF-1 levels, affect insulin sensitivity, or impair glucose tolerance. Euglycemic clamp studies in animals demonstrated that chronic AOD-9604 treatment showed no adverse effect on insulin sensitivity, distinguishing it from intact hGH which can cause glucose intolerance and insulin resistance. This metabolic selectivity means the peptide targets adipose tissue without the growth-promoting effects, sodium retention, tissue edema, or carbohydrate metabolism disruptions associated with growth hormone therapy. The peptide works peripherally on fat cells rather than centrally on appetite-regulating pathways in the hypothalamus.

Cartilage and Bone Effects

Emerging research suggests AOD-9604 may have regenerative properties beyond fat metabolism. Studies in rabbit osteoarthritis models show that intra-articular injections of AOD- 9604 enhanced cartilage regeneration, reduced lameness duration, and improved both gross morphological and histopathological scores of articular cartilage. The mechanism for these cartilage effects is not fully understood but may involve growth factor- independent tissue repair pathways, anti-inflammatory effects, and enhanced cellular regeneration in cartilaginous tissues. This represents a distinct mechanism from the adipose tissue effects and remains an active area of investigation.

Benefits

information found in this book should be regarded as advice and opinions based on my experience and research. AOD-9604 has been studied in both laboratory and clinical settings. The evidence for benefits varies significantly between preclinical animal studies and human clinical trials.

Fat Metabolism and Body Composition

Animal studies demonstrated clear effects on fat metabolism and body weight: In obese Zucker rats, daily oral AOD-9604 treatment (500 mcg/kg body weight) for 19 days reduced body weight gain by over 50% compared to controls (15.8 ± 0.6 g vs 35.6 ± 0.8 g). Adipose tissues showed increased lipolytic activity. In genetically obese mice and ob/ob mice, chronic treatment reduced body weight and body fat accumulation without affecting food intake, demonstrating that effects were mediated through increased energy expenditure rather than appetite suppression. Treatment increased fat oxidation rates and enhanced expression of beta-3 adrenergic receptors in adipose tissue. Human clinical trial results were more modest: In a 12-week Phase IIa trial with approximately 300 participants, subjects receiving AOD-9604 at 1 mg daily lost an average of 2.6 kg compared to 0.8 kg in the placebo group, representing an additional 1.8 kg of weight loss. Interestingly, higher doses (10 mg/day) did not produce greater weight reduction, suggesting a plateau effect. However, in the larger 24-week Phase IIb trial with 502 obese participants (BMI 30-45 kg/m²) receiving 0.25 mg, 0.5 mg, or 1 mg daily, AOD-9604 failed to demonstrate statistically significant weight loss compared to placebo. This led to termination of development in 2007. Clinical studies showed preferential reduction of abdominal and visceral fat deposits in responders, though overall efficacy remained inconsistent across the study population.

Cartilage Regeneration and Joint Health

Research in rabbit osteoarthritis models demonstrated significant cartilage protective and regenerative effects: Intra-articular injections of 0.25 mg AOD-9604 weekly for 4-7 weeks enhanced cartilage regeneration in collagenase-induced knee osteoarthritis. Combined AOD-9604 and hyaluronic acid (HA) injections were more effective than HA or AOD-9604 alone, showing synergistic effects. The combination group had significantly lower gross morphological and histopathological degeneration scores and shorter lameness periods. Treated joints showed reduced cartilage erosion, less chondrocyte cloning in transitional and radial zones, and improved overall cartilage structure compared to saline controls. These findings suggest potential therapeutic applications for osteoarthritis, though human trials have not been conducted.

Safety Profile

The most consistent finding across all studies was AOD-9604’s excellent safety profile: information found in this book should be regarded as advice and opinions based on my experience and research. No clinically relevant changes in IGF-1 levels across six clinical trials. No negative effects on glucose metabolism or insulin sensitivity, as demonstrated by oral glucose tolerance testing. No anti-AOD9604 antibodies detected in any participants at any time point, indicating the peptide is not immunogenic. No withdrawals or serious adverse events related to AOD-9604 intake across all studies. Safety profile indistinguishable from placebo in controlled trials.

What the Science Shows

Ng et al. (2000) Published in Hormone Research. Metabolic studies of AOD-9604 in obese Zucker rats. Key findings: Daily oral AOD-9604 (500 mcg/kg) for 19 days reduced body weight gain by over 50% compared to controls Adipose tissues showed increased lipolytic activity No adverse effect on insulin sensitivity, as demonstrated with euglycemic clamp techniques Suggested potential as an orally usable and safe therapeutic agent for obesity

Heffernan et al. (2001) Published in Endocrinology. Effects of hGH and AOD-9604 on lipid metabolism in obese mice and beta-3-AR knockout mice. Key findings: Both hGH and AOD-9604 reduced body weight and body fat in obese mice following 14 days of chronic administration Treatment increased expression levels of beta-3-AR RNA in adipose tissue Both compounds increased repressed beta-3-AR RNA levels in obese mice to levels comparable with lean mice In beta-3-AR knockout mice, both hGH and AOD-9604 failed to produce changes in body weight or increase lipolysis, confirming the importance of this receptor pathway

Stier et al. (2013) Published in Journal of Endocrinology and Metabolism. Safety and tolerability data from six clinical trials. Key findings: Over 900 participants across six randomized, double-blind, placebo-controlled trials

information found in this book should be regarded as advice and opinions based on my experience and research. No effect on serum IGF-1 levels, confirming AOD-9604 does not activate the hGH/IGF-1 pathway No negative effects on carbohydrate metabolism as measured by oral glucose tolerance testing No anti-AOD9604 antibodies detected in any subject Very good safety and tolerability profile indistinguishable from placebo No withdrawals or serious adverse events related to AOD-9604

Kwon and Park (2015) Published in Annals of Clinical and Laboratory Science. Intra-articular AOD-9604 in rabbit osteoarthritis model. Key findings: Weekly injections of 0.25 mg AOD-9604 for 4-7 weeks in collagenase-induced knee OA Mean gross morphological and histopathological scores significantly lower in AOD-9604 groups compared to saline control Combined AOD-9604 and hyaluronic acid produced better results than either treatment alone Lameness period significantly shorter in combination treatment group Intra-articular AOD-9604 enhanced cartilage regeneration

Misra (2013) Published in Current Cardiology Reviews. Review of obesity pharmacotherapy including AOD- 9604. Key findings: 12-week trial: subjects receiving 1 mg/day AOD-9604 lost average of 2.6 kg compared to 0.8 kg in placebo group Development terminated in 2007 after 24-week trial of 536 subjects failed to induce significant weight loss Noted that despite promising mechanism, clinical efficacy was insufficient for regulatory approval Sources: Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182- 5189. https://pubmed.ncbi.nlm.nih.gov/11713213/

information found in this book should be regarded as advice and opinions based on my experience and research. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. https://www.jofem.org/index.php/jofem/article/view/157 Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-432. Misra M. Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33-54. https://pubmed.ncbi.nlm.nih.gov/23463942/

Dosing Protocol

AOD-9604 is available in injectable form. The peptide has also been formulated for oral administration in some research settings, though subcutaneous injection is the most common route.

Injectable Protocol (Subcutaneous) Standard Protocol: Dose: 250 to 500 mcg per day Frequency: Daily, preferably in the morning on an empty stomach Cycle length: 8 to 12 weeks Break: 4 to 8 weeks between cycles Conservative Protocol: Dose: 250 mcg per day Frequency: 5 days per week (weekdays) Duration: Start here to assess tolerance and response Extended Protocol: Dose: 500 mcg per day

Frequency: Daily

Duration: Up to 24 weeks (based on longest clinical trial) Clinical trials used doses ranging from 0.25 mg to 10 mg daily. Interestingly, higher doses (10 mg) did not produce better results than 1 mg, suggesting a dose-response ceiling. The 250-500 mcg daily range appears optimal for most users. The peptide has a short half-life (approximately 4 minutes in serum based on in vitro degradation studies), which is why daily administration is recommended. Peak effects occur when the peptide is administered in a fasted state with low insulin levels.

Timing Considerations

information found in this book should be regarded as advice and opinions based on my experience and research. For optimal fat-mobilizing effects, AOD-9604 should be administered during a fasted state, typically first thing in the morning after an overnight fast of 8-10 hours. This timing maximizes the peptide’s ability to stimulate fat breakdown without metabolic interference from insulin. After injection, wait 30 to 60 minutes before consuming any food or caloric beverages to allow the peptide to initiate lipolytic signaling. Many users combine morning injection with light fasted cardio or normal activities during this window to enhance fat oxidation. Black coffee or tea without additives is acceptable during the waiting period.

Intra-articular Protocol (For Joint Applications) Based on animal studies showing cartilage regeneration benefits: Dose: 0.25 mg per affected joint

Frequency: Weekly injections

Duration: 4 to 7 weeks Administration: Intra-articular injection using ultrasound guidance (requires medical professional) Note: Consider combination with hyaluronic acid for enhanced cartilage regeneration based on animal research showing synergistic effects This application is based solely on animal research and has not been validated in human trials.

Draw Volumes by Vial Size

6 mg Vial with 1.2 mL Bacteriostatic Water (5 mg/mL concentration) Dose Volume Units on Syringe 250 mcg 0.05 mL 5 units 500 mcg 0.10 mL 10 units 1 mg 0.20 mL 20 units Vial duration at 500 mcg daily: 12 days 6 mg Vial with 2 mL Bacteriostatic Water (3 mg/mL concentration) Dose Volume Units on Syringe 250 mcg 0.083 mL 8.3 units 500 mcg 0.167 mL 16.7 units 1 mg 0.33 mL 33 units Vial duration at 500 mcg daily: 12 days 10 mg Vial with 2 mL Bacteriostatic Water (5 mg/mL concentration) Dose Volume Units on Syringe 250 mcg 0.05 mL 5 units 500 mcg 0.10 mL 10 units information found in this book should be regarded as advice and opinions based on my experience and research. 1 mg 0.20 mL 20 units Vial duration at 500 mcg daily: 20 days

Reconstitution

Materials Needed: AOD-9604 vial (lyophilized powder) Bacteriostatic water Sterile syringe for reconstitution Alcohol swabs Instructions: 1. Wipe the AOD-9604 vial stopper and bacteriostatic water vial with alcohol swabs 2. Draw 1.2 to 2 mL of bacteriostatic water (depending on desired concentration) 3. Insert needle through rubber stopper at an angle 4. Let water trickle slowly down the inside wall of the vial 5. Do not inject directly onto the powder or shake vigorously 6. Gently swirl until fully dissolved 7. The solution should be clear and colorless 8. If solution is cloudy or contains particles, do not use Unlike GHK-Cu which has a distinctive blue color, AOD-9604 should be clear and colorless after reconstitution. Any cloudiness, discoloration, or visible particles indicates degradation or contamination.

Side Effects

AOD-9604 has an exceptional safety profile based on clinical trials involving over 900 participants. The peptide was well-tolerated with minimal adverse effects.

Common (Mild) Injection site reactions including redness, swelling, or mild irritation Transient headache Mild fatigue, particularly when combined with fasted cardio These effects were generally mild and occurred at rates similar to placebo in controlled trials.

Rare

Nausea (typically when administered with food or in non-fasted state)

Dizziness

information found in this book should be regarded as advice and opinions based on my experience and research. Temporary increase in hunger (rebound effect after fasted-state administration)

Not Observed

Clinical trials specifically monitored for adverse effects associated with full-length growth hormone. The following were NOT observed with AOD-9604: No elevation of IGF-1 levels No insulin resistance or impaired glucose tolerance No sodium retention or tissue edema No carpal tunnel syndrome No joint pain or arthralgias No antibody formation (no immunogenicity) No serious adverse events No study withdrawals related to the peptide This favorable safety profile was the most consistent finding across all clinical trials, even though efficacy was insufficient for regulatory approval.

Contraindications and Precautions

Do Not Use If You Have: Active cancer or tumors (theoretical concern, though no evidence of tumor promotion in studies) Known hypersensitivity to AOD-9604 or any component Pregnancy or breastfeeding (no safety data available)

Use Caution With: Cardiovascular disease (monitor for any unexpected effects, though trials showed no cardiac concerns) Severe obesity with metabolic complications (medical supervision recommended) Concurrent use of other fat-loss compounds or stimulants Diabetes or glucose metabolism disorders (though AOD-9604 does not affect glucose metabolism, monitoring is prudent)

Drug Interactions: No significant drug interactions have been reported in clinical trials. AOD-9604 does not appear to interact with common medications. However, theoretical interactions may exist with: Other beta-adrenergic agonists (potential additive effects) Appetite suppressants or weight loss medications (combined mechanisms not studied) information found in this book should be regarded as advice and opinions based on my experience and research. Growth hormone or growth hormone secretagogues (unclear interactions)

Regulatory Status: AOD-9604 is not approved by the FDA or any major regulatory authority for medical use. It is available as a research peptide only. The peptide does not have GRAS (Generally Recognized as Safe) status for dietary supplement use, despite some marketing claims to the contrary. Any such claims should be viewed with skepticism. In 2023, the FDA classified many compounding peptides as Category 2 bulk drug substances, which affects legal availability through compounding pharmacies.

WADA Status: AOD-9604 is prohibited in sport. It is included on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) as a growth hormone releasing factor. Athletes subject to drug testing should not use this peptide. Consult a qualified healthcare provider before use.

AOD-9604 vs Other Peptides and Compounds

AOD-9604 occupies a unique position among peptides and weight loss compounds due to its specific mechanism and mixed efficacy profile.

vs Full-Length Growth Hormone (hGH) AOD-9604 was designed to isolate the lipolytic effects of growth hormone without the broader metabolic consequences: Similarities: Both stimulate lipolysis and can reduce body fat Key Differences: AOD-9604 does not elevate IGF-1, does not cause insulin resistance or glucose intolerance, does not promote muscle growth or tissue hypertrophy, does not cause sodium retention or edema, has no effect on bone density or growth, and carries minimal side effect risk Trade-off: AOD-9604 has significantly reduced potency compared to full-length hGH. While safer, it is also much less effective for fat loss.

vs GLP-1 Receptor Agonists (Semaglutide, Tirzepatide) GLP-1 agonists represent the current gold standard for pharmaceutical weight loss: Mechanism Difference: GLP-1 agonists work through appetite suppression and delayed gastric emptying, while AOD-9604 works through peripheral fat metabolism without affecting hunger Efficacy: GLP-1 agonists produce 10-24% body weight loss in clinical trials, while AOD-9604 produced 1.8 kg additional weight loss over 12 weeks (roughly 2% for a 90 kg person) information found in this book should be regarded as advice and opinions based on my experience and research. Side Effects: GLP-1 agonists commonly cause nausea, vomiting, and gastrointestinal distress, while AOD-9604 has minimal side effects Conclusion: GLP-1 agonists are vastly more effective but less well-tolerated. AOD-9604 cannot compete with GLP-1 drugs for weight loss efficacy.

vs Other Growth Hormone Secretagogues (CJC-1295, Ipamorelin) Growth hormone releasing peptides stimulate the body’s natural GH production: Mechanism: CJC-1295/Ipamorelin increase endogenous GH pulses, while AOD-9604 mimics only GH’s fat-burning domain Effects: Secretagogues promote fat loss, muscle preservation, improved recovery, and sleep quality through elevated GH/IGF-1, while AOD-9604 targets only fat metabolism Safety: Secretagogues may affect glucose metabolism and carry GH-related risks, while AOD- 9604 has superior safety profile Use Case: Secretagogues offer broader body recomposition benefits, while AOD-9604 is more targeted and safer but less effective

vs Traditional Stimulants (Caffeine, Ephedrine) Traditional fat burners work through thermogenesis and increased energy expenditure: Mechanism: Stimulants increase metabolic rate and suppress appetite through central nervous system activation, while AOD-9604 works peripherally on fat tissue Side Effects: Stimulants cause anxiety, jitteriness, elevated heart rate, and sleep disruption, while AOD-9604 has minimal CNS effects Efficacy: Both have modest effects, but stimulants provide immediate subjective energy effects while AOD-9604 works more subtly

Clinical Reality

The termination of AOD-9604’s development in 2007 after failing Phase IIb trials reflects an important reality: the peptide did not produce clinically significant weight loss in large-scale human trials, despite promising preclinical data. For individuals seeking significant weight loss, lifestyle interventions (diet and exercise) or FDA-approved medications (particularly GLP-1 agonists) are more evidence-based approaches. AOD-9604 may have utility as an adjunct for those who cannot tolerate or do not respond to other interventions, or for research purposes studying fat metabolism pathways. The peptide’s most promising applications may lie outside obesity treatment, particularly in cartilage regeneration and osteoarthritis, where animal studies show more compelling results.

Success Tips

Set Realistic Expectations

information found in this book should be regarded as advice and opinions based on my experience and research. AOD-9604 is not a miracle weight loss solution. Clinical trials showed modest results at best, with the largest trial failing to demonstrate significant efficacy. Expect gradual, incremental effects if you respond to the peptide at all. Typical realistic outcomes: First 4 weeks: Minimal visible changes, possible subtle improvements in body composition Weeks 4-8: Some users may notice reduced abdominal fat or improved definition when combined with diet and exercise Weeks 8-12: Continued gradual fat loss in responders, but total weight change may be only 2-4 kg Individual response varies significantly. Some users are non-responders.

Optimize Administration Timing

For maximum lipolytic effects: Inject first thing in the morning after an overnight fast of 8-10 hours Wait 30-60 minutes before eating to allow the peptide to work in a low-insulin state Consider light fasted cardio (walking, easy cycling) during the 30-60 minute window post- injection Black coffee or plain tea is acceptable and may enhance fat oxidation

AOD-9604 is Not a Replacement for Diet and Exercise The peptide works by increasing fat breakdown, but this effect is meaningless if you are in a caloric surplus. AOD-9604 does not suppress appetite or reduce food intake. For the peptide to have any effect, you must be in a caloric deficit through diet and exercise. Best practices: Maintain a moderate caloric deficit (300-500 calories below maintenance) Prioritize protein intake (1.6-2.2 g/kg body weight) to preserve lean mass Engage in regular resistance training to maintain muscle during fat loss Include cardiovascular exercise to create additional caloric deficit

Monitor and Assess Response

Since individual response varies, systematic tracking is essential: Track body weight weekly (same time, same conditions) Take progress photos every 2 weeks Measure key body sites (waist, hips, thigh circumference) biweekly If no changes after 6-8 weeks, you may be a non-responder

Consider Stacking (With Caution)

information found in this book should be regarded as advice and opinions based on my experience and research. AOD-9604 may work synergistically with other compounds, though evidence is limited: With hyaluronic acid for joint applications (animal evidence supports this) With other healing peptides like BPC-157 or TB-500 for comprehensive tissue repair Potentially with CJC-1295/Ipamorelin for broader metabolic effects (no research, proceed cautiously) Do not combine with GLP-1 agonists without medical supervision, as mechanisms and safety have not been studied.

Storage and Handling

Before Reconstitution: Store lyophilized (powder) vials at -20°C (-4°F) or below for long-term storage Can be stored at 2-8°C (35-46°F) for shorter periods (up to 3 months) Protect from light and moisture Stable for months to years when stored properly in lyophilized form

After Reconstitution: Refrigerate at 2-8°C (35-46°F) Use within 30 days for optimal potency Do not freeze after reconstitution Keep away from direct light The solution should remain clear and colorless. If it becomes cloudy, discolored, or contains particles, discard immediately

Degradation and Stability: AOD-9604 has a very short half-life in biological systems. In vitro studies in rat plasma showed approximately 4 minutes half-life at room temperature, with complete degradation by 56 minutes. The peptide degrades through amino-terminal truncation with sequential amino acid removal. This rapid degradation is why the peptide requires daily administration and why timing relative to meals matters. The short biological half-life also contributes to the excellent safety profile, as the peptide does not accumulate in the body.

Legal Status

United States:

information found in this book should be regarded as advice and opinions based on my experience and research. AOD-9604 is not approved by the FDA for any medical indication. It is not a prescription drug, over-the-counter medication, or approved dietary supplement ingredient. The peptide is available as a research chemical for laboratory use only. Marketing or selling AOD-9604 for human consumption is not permitted under current FDA regulations. In 2023, the FDA classified many compounding peptides, including various growth hormone derivatives, as Category 2 bulk drug substances. This classification affects availability through compounding pharmacies. Claims that AOD-9604 has GRAS (Generally Recognized as Safe) status for dietary supplement use are inaccurate and should be viewed with skepticism.

International: AOD-9604 is not approved for medical use by the European Medicines Agency (EMA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), or the Therapeutic Goods Administration (TGA) in Australia, despite being developed in Australia. Regulatory status varies by country. In most jurisdictions, the peptide is available only for research purposes.

WADA Prohibited Status: AOD-9604 is prohibited in sport at all times under the World Anti-Doping Agency (WADA) Prohibited List. It is classified under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). The peptide is banned both in-competition and out-of-competition. Athletes subject to drug testing by WADA or national anti-doping organizations should not use AOD-9604. Detection methods exist, and the peptide can be identified in urine and blood samples for several days post-administration.

Product Source:

Pharma-grade research peptides that are third party tested.

www.peptideprolab.com – Use the discount code “JOEYFIRESTONE” at checkout for 10% off

GET AOD-9604 HERE

Frequently Asked Questions

How long until I see results from AOD-9604? Individual response varies significantly. Some users may notice subtle body composition changes within 4-6 weeks, while others may be non-responders. Clinical trials showed modest weight loss (1.8 kg over 12 weeks) in responders, but the largest trial failed to show significant information found in this book should be regarded as advice and opinions based on my experience and research. effects. Do not expect dramatic or rapid weight loss. Any results require consistent use combined with proper diet and exercise.

Does AOD-9604 suppress appetite or make me hungry? No, AOD-9604 is appetite-neutral. Unlike GLP-1 agonists which reduce hunger, AOD-9604 works peripherally on fat tissue and does not affect central appetite regulation. Some users report increased hunger as a rebound effect after fasted-state administration, which is a normal physiological response to increased fat oxidation. This is not a side effect but rather an indication that the peptide is mobilizing fat stores.

Can I use AOD-9604 with other peptides? AOD-9604 can potentially be stacked with other peptides, though specific combinations have not been studied in clinical trials. It appears compatible with healing peptides like BPC-157 or TB- 500 for tissue repair. Combination with hyaluronic acid for joint applications is supported by animal research. Exercise caution when combining with growth hormone secretagogues (CJC- 1295, Ipamorelin) or other metabolic compounds. Do not combine with GLP-1 agonists without medical supervision.

Why did AOD-9604 fail clinical trials if it works in animals? This is a common phenomenon in drug development. Animal models of obesity (genetically obese mice, Zucker rats) showed robust responses to AOD-9604, with 50% reductions in weight gain and clear metabolic improvements. However, human obesity is far more complex, involving psychological, behavioral, environmental, and genetic factors that cannot be replicated in controlled animal studies. The peptide’s mechanism may be insufficient to overcome the complexity of human metabolic regulation. Additionally, the short half-life and rapid degradation may limit efficacy in humans compared to continuous exposure in animal studies.

Is AOD-9604 better than GLP-1 drugs like semaglutide? No. GLP-1 receptor agonists (semaglutide, tirzepatide) are vastly more effective for weight loss, producing 10-24% body weight reduction in clinical trials compared to AOD-9604’s 1.8 kg additional loss over 12 weeks. AOD-9604’s advantages are its superior safety profile, lack of gastrointestinal side effects, and preservation of appetite. If significant weight loss is the goal, GLP-1 drugs are the evidence-based choice. AOD-9604 may have utility for individuals who cannot tolerate GLP-1 agonists or as an adjunct to other interventions.

Does AOD-9604 affect hormones like testosterone or thyroid? No. AOD-9604 does not affect hormone levels. Clinical trials specifically monitored for hormonal changes and found no effects on IGF-1, insulin, glucose, or other endocrine parameters. The peptide does not interact with the hypothalamic-pituitary axis and works peripherally on adipose tissue. It should not affect testosterone, estrogen, thyroid hormones, or cortisol levels.

Can AOD-9604 help with joint pain or cartilage repair? information found in this book should be regarded as advice and opinions based on my experience and research. Possibly, but only animal research exists. Studies in rabbit osteoarthritis models showed that intra-articular injections of AOD-9604 enhanced cartilage regeneration, reduced lameness, and improved joint structure. Combined with hyaluronic acid, the effects were even more pronounced. However, no human trials have been conducted for this application. The mechanism is unknown and may involve anti-inflammatory effects or growth factor-independent tissue repair pathways. This remains an investigational use.

Is oral AOD-9604 effective? Early animal studies tested both oral and injectable formulations, with oral doses showing activity. Human trials used subcutaneous injection as the primary route. Oral bioavailability is likely lower due to gastrointestinal degradation, though some research suggested approximately 40% oral bioavailability based on radioactivity distribution studies. Injectable administration is preferred for consistency and reliability.

References

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. 2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182- 5189. https://pubmed.ncbi.nlm.nih.gov/11713213/ 3. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-507. https://pubmed.ncbi.nlm.nih.gov/10950816/ 4. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. 5. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-432. 6. Misra M. Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33-54. https://pubmed.ncbi.nlm.nih.gov/23463942/ 7. Moré M, Keller A. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab. 2014;4(3):64-77. 8. Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000;25(3):287-298. https://pubmed.ncbi.nlm.nih.gov/11116208/

information found in this book should be regarded as advice and opinions based on my experience and research.